

primary studies - published RCT

Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.

Code: PM10862158

Year: 2000 Date: 2004

Author: Robinson M

Study design (if review, criteria of inclusion for studies)

20 week, placebo-controlled, and randomized, double blind, crossover trial

Participants

12 CF patients, aged 6-29

Interventions

montelukast or placebo

Outcome measures

At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured.

Main results

In montelukast group significant improvement in FEV1 (mean +/- SD, 54.6 +/- 22.6 before and 62 +/- 19.0 after treatment, p=0.0112) and FEF25/75% (28.9 +/- 23.0 before and 37.5 +/- 25.5 after treatment, p=0.0053) were observed. Compared with placebo montelukast significantly improved FEV1 (p=0.0032), PEF (p=0.0298) and FEF25/75% (p=0.0091). There was no significant difference in VC, TGV, Raw and RV. Montelukast compared with placebo significantly decreased cough (p

[3.0.CO;2-H" target=" blank">http://dx.doi.org/10.1002/1099-0496\(200007\)30:1<16::AID-PPUL4>3.0.CO;2-H](http://dx.doi.org/10.1002/1099-0496(200007)30:1<16::AID-PPUL4>3.0.CO;2-H)

See also

Pediatr Pulmonol. 2000 Jul;30(1):16-24.

Keywords

Adolescent; Adult; Anti-Bacterial Agents; Child; Leukotriene Antagonists; pharmacological_intervention; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Montelukast;